Fulgent Genetics is rated Hold due to strong diagnostic revenue growth but an unproven transition into integrated precision medicine. FLGT's diagnostics business leads with rapid genome tests and ...

Q4 2025 earnings call recap: revenue beat, MyRisk/GeneSight growth, 2026 guidance, new test launches & key risks—read now.

GeneDx Holdings (NASDAQ:WGS) stock is trading higher on Tuesday. The genetic testing company reported a third-quarter EPS loss of $(0.31), compared to $(1.64) reported a year ago, beating the ...

Myriad Genetics specializes in molecular diagnostic testing, offering genetic screening and analysis to help inform medical decisions in cancer, women’s health, and mental health. Its products are ...

CEO Sam Raha opened the call by highlighting a challenging Q1 2025, with revenue of $196 million, representing a 3% year-over-year decline. He noted strong performance in prenatal oncology tests and ...